Glenmark Readying Xolair Biosimilar Challenge

Glenmark has received US FDA clearance of an IND to start clinical studies with a proposed biosimilar version of Xolair. The Indian company appears confident of addressing any price-related challenges although the targeted launch is still some years away.

More from Business

More from Generics Bulletin